Inferra AIResearch Tools

Inferra AI / Company / GILD

Gilead Sciences

GILD · Health Care

Last earnings Oct 29, 2026

Key results

Revenuequarter

3%

revenues increased 3% to $7.8 billion compared to the same period in 2024, broken down as follows Total third quarter 2025 product sales decreased 2% to $7.3 billion compared to the same period in 2024, primarily driven by lower Veklury (remdesivir) and Cell Therapy sales

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

EPSquarter

$2.43

Diluted earnings per share ( EPS ) was $2.43 in the third quarter 2025 compared to $1.00 in the same period in 2024.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

The increase was primarily driven by a prior year pre-tax in-process research and development ( IPR D ) impairment charge of $1.75 billion that did not repeat in the current period, as well as the $400 million increase in other revenue mentioned above, lower acquired IPR D expenses and higher net unrealized gains on equity investments in the current period, partially offset by higher tax expense.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Non-GAAP EPSquarter

$2.47

Non-GAAP diluted EPS of $2.47 in the third quarter 2025 compared to $2.02 in the same period in 2024.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

The increase was primarily driven by the $400 million increase in other revenue mentioned above and lower acquired IPR D expenses.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Tax Rate Product gross marginquarter

78.6%

Third Quarter 2025 Product Gross Margin, Operating Expenses and Effective Tax Rate Product gross margin remained relatively flat at 78.6% in the third quarter 2025 compared to 79.1% in the same period in 2024.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Gross marginquarter

86.5%

Non-GAAP product gross margin also remained relatively flat at 86.5% in the third quarter 2025 compared to 86.8% in the same period in 2024.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

AI analysis

Q3 2025 · reported Oct 30, 2025

Based on: Earnings release + parent 8-K — transcript not held

EPS · Q3 2025
$2.43
+143.0% vs year ago computed from stated figures
EX-99 · Oct 30, 2025
Tax Rate Product gross margin · Q3 2025
78.6%
-0.5 pts vs year ago computed from stated figures
EX-99 · Oct 30, 2025
Non-GAAP EPS · Q3 2025
$2.47
+22.3% vs year ago computed from stated figures
EX-99 · Oct 30, 2025
Gross margin · Q3 2025
86.5%
+7.8 pts vs prior quarter computed from stated figures
-0.3 pts vs year ago computed from stated figures
EX-99 · Oct 30, 2025

The quarter in charts

GAAP gross margin

Percent of revenue, as stated

0%45%90%79.1%Same quarter last year78.6%Q3 2025

EX-99 · Oct 30, 2025 Margin values as stated in the release.

Diluted EPS — GAAP

Per diluted share, as stated

0123$1.00Same quarter last year$2.43Q3 2025 (quarter)

EX-99 · Oct 30, 2025 EPS values as stated in the release.

Headline figures

MetricQ3 2025Prior qtrYear ago
Revenue3%2%—
EPS$2.43$1.56$1.00
Non-GAAP EPS$2.47$2.01$2.02
Tax Rate Product gross margin78.6%78.7%79.1%
Gross margin86.5%78.7%86.8%

EX-99 · Oct 30, 2025

Guidance · company-stated

Direction: Reiterated

Revenue

“October 30, 2025 3 Guidance and Outlook For the full-year, Gilead expects (in millions, except per share amounts) October 30, 2025 Guidance Low End High End Comparison to Prior Guidance Product sales $ 28,400 $ 28,700 Previously $28,300 to $28,700 Product sales excluding Veklury $ 27,400 $ 27,700 Previously $27,300 to $27,700 Veklury $ 1,000 $ 1,000 Unchanged Diluted EPS $ 6.65 $ 6.85 Previously $5.85 to $6.15 Non-GAAP diluted EPS $ 8.05 $ 8.25 Previously $7.95 to $8.25 Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2025 guidance is provided in the accompanying tables.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Tax Rate Product gross margin78.6%
Gross margin86.5%

Capital allocation

Dividend$1.0B

As of September 30, 2025, Gilead had $9.4 billion of cash, cash equivalents and marketable debt securities compared to $10.0 billion as of December 31, 2024.

Company-stated claims

Oct 29, 2026

Historical · doubled · revenue

“Our HIV business grew 18% and HIV prevention sales nearly doubled year-over-year.”

EX-99 · Oct 29, 2026
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Reiterated

Revenue: “October 30, 2025 3 Guidance and Outlook For the full-year, Gilead expects (in millions, except per share amounts) October 30, 2025 Guidance Low End High End Comparison to Prior Guidance Product sales $ 28,400 $ 28,700 Previously $28,300 to $28,700 Product sales excluding Veklury $ 27,400 $ 27,700 Previously $27,300 to $27,700 Veklury $ 1,000 $ 1,000 Unchanged Diluted EPS $ 6.65 $ 6.85 Previously $5.85 to $6.15 Non-GAAP diluted EPS $ 8.05 $ 8.25 Previously $7.95 to $8.25 Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2025 guidance is provided in the accompanying tables.”

Revenue — Reiterated (“Unchanged”)
“October 30, 2025 3 Guidance and Outlook For the full-year, Gilead expects (in millions, except per share amounts) October 30, 2025 Guidance Low End High End Comparison to Prior Guidance Product sales $ 28,400 $ 28,700 Previously $28,300 to $28,700 Product sales excluding Veklury $ 27,400 $ 27,700 Previously $27,300 to $27,700 Veklury $ 1,000 $ 1,000 Unchanged Diluted EPS $ 6.65 $ 6.85 Previously $5.85 to $6.15 Non-GAAP diluted EPS $ 8.05 $ 8.25 Previously $7.95 to $8.25 Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2025 guidance is provided in the accompanying tables.”

Revenue — Lowered (“Reduction”)
“These risks and uncertainties include those relating to Gilead s ability to achieve its full year 2025 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues, the impact of the Inflation Reduction Act, changes in U.”

Classified from the release's primary full-year outlook statement.

Capital allocation

As of September 30, 2025, Gilead had $9.4 billion of cash, cash equivalents and marketable debt securities compared to $10.0 billion as of December 31, 2024.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

During the third quarter 2025, Gilead paid dividends of $1.0 billion and repurchased $435 million of common stock.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Corporate The Board declared a quarterly dividend of $0.79 per share of common stock for the fourth quarter of 2025.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

The dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 15, 2025.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Future dividends will be subject to Board approval.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Strategy & priorities

trade policies, including tariffs Gilead s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy Gilead s ability to accelerate or sustain revenues for its virology, oncology and other programs Gilead s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the acquisitions of Interius, and the arrangements with Pregene and PEPFAR the risk that Gilead s U.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Risks & headwinds

Cell Therapy product sales decreased 11% to $432 million in the third quarter 2025 compared to the same period in 2024, reflecting ongoing competitive headwinds.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

The financial guidance is subject to a number of risks and uncertainties.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Key Updates Since Our Last Quarterly Release Virology Announced settlement agreements to resolve Biktarvy patent litigation with generic manufacturers Lupin Ltd.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

These risks and uncertainties include those relating to Gilead s ability to achieve its full year 2025 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues, the impact of the Inflation Reduction Act, changes in U.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

trade policies, including tariffs Gilead s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy Gilead s ability to accelerate or sustain revenues for its virology, oncology and other programs Gilead s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the acquisitions of Interius, and the arrangements with Pregene and PEPFAR the risk that Gilead s U.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

What changed vs prior quarter

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

EPS — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Non-GAAP EPS — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Gilead Sciences — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Documents

Earnings deck slides

1 deck with slide view

Gilead Sciences — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Genmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health CareJohnson & Johnson (JNJ) Health Care

Filings

113 documents

Earnings releases

46 documents

Presentations

2 documents

Transcripts

0 documents

No transcripts for Gilead Sciences are held in this edition of the library.

Mentioned by

3 companies

Other tracked companies whose held documents mention Gilead Sciences by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.